modified fibroblast growth factor 21 (fgf-21) for use in non-alcoholic steatohepatitis (nash) treatment methods

摘要

the present invention relates to methods for the treatment of a patient having nash that has been determined to have a particular limit level of pro-c3 in the serum (for example, greater than 10 ng / ml), by administering to the patient a modified fibroblast growth factor 21 (fgf-21) in an amount and often enough to treat nash. methods are also provided for monitoring the responsiveness of a patient having nash to treatment with a modified fgf-21, the method comprising: determining the level of pro-c3 in the serum in a patient blood sample obtained during or after the treatment, in which: a decrease in the level of pro-c3 in the serum in the patient's blood sample obtained during or after treatment, compared to the level of pro-c3 in the serum in a patient's blood sample obtained before treatment with the modified fgf-21, indicates that the patient is responsive to treatment with the modified fgf-21.